Resmetirom - Generic Drug Details

What are the generic sources for resmetirom and what is the scope of freedom to operate?

Resmetirom is the generic ingredient in one branded drug marketed by Madrigal and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Resmetirom has one hundred and seventeen patent family members in thirty-six countries.

One supplier is listed for this compound.

Summary for resmetirom

International Patents:	117
US Patents:	6
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	9
Patent Applications:	2,496
What excipients (inactive ingredients) are in resmetirom?	resmetirom excipients list
DailyMed Link:	resmetirom at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for resmetirom

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for resmetirom

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Naga P. Chalasani	PHASE2
Madrigal Pharmaceuticals, Inc.	PHASE2
Nabiqasim Industries (Pvt) Ltd	PHASE4

See all resmetirom clinical trials

Pharmacology for resmetirom

Drug Class	Thyroid Hormone Receptor beta Agonist
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2C8 Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors Thyroid Hormone Receptor beta Agonists

Anatomical Therapeutic Chemical (ATC) Classes for resmetirom

A05BA	Liver therapy
A05B	LIVER THERAPY, LIPOTROPICS
A05	BILE AND LIVER THERAPY
A	Alimentary tract and metabolism

US Patents and Regulatory Information for resmetirom

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-001	Mar 14, 2024		RX	Yes	No
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-002	Mar 14, 2024		RX	Yes	No
Madrigal	REZDIFFRA	resmetirom	TABLET;ORAL	217785-003	Mar 14, 2024		RX	Yes	Yes

International Patents for resmetirom

Country	Patent Number	Title	Estimated Expiration
Japan	2015535817
Japan	6765408
South Korea	20080019297	PYRIDAZINONE DERIVATIVES AS THYROID HORMONE RECEPTOR AGONISTS
South Korea	20150056630

RESMETIROM: Market Dynamics and Financial Trajectory

Last updated: March 10, 2026

What is the current status of Resmetirom in the pharmaceutical market?

Resmetirom (MGL-3196) is an oral, liver-selective thyroid hormone receptor-beta (THR-β) agonist developed for treating non-alcoholic steatohepatitis (NASH) and other metabolic liver diseases. It is in late-stage clinical development, primarily targeting NASH, which affects approximately 5-10% of the global population.

How is Resmetirom positioned within the NASH treatment landscape?

Resmetirom competes in a crowded pipeline where few candidates have advanced beyond Phase III trials. Key competitors include:

• Ocaliva (obeticholic acid) from Intercept Pharmaceuticals
• Aramchol (from Galmed Pharmaceuticals)
• Resmetirom's differentiation lies in its liver-focal mechanism, oral administration, and anti-fibrotic potential.

Market Size and Growth Projections

• The global NASH market is valued at approximately $4.4 billion in 2022 (Source: FMI)
• It is expected to grow at a compound annual growth rate (CAGR) of 23% from 2022 to 2028
• The broader metabolic disease market, including NASH, is projected to reach $10 billion by 2030

What is the regulatory and clinical development status of Resmetirom?

• Resmetirom completed pivotal Phase III trials (VOYAGE and MAESTRO-NASH) with positive preliminary results indicating significant reduction in liver fat and improvement in fibrosis markers.
• The company announced plans for a Biologics License Application (BLA) submission in 2024, contingent on trial data.
• The FDA has granted Resmetirom Fast Track designation, expediting review processes.

What are the financial expectations for Resmetirom?

Assessing the financial trajectory involves evaluating development costs, potential revenues, licensing, and commercialization rights.

Revenue Projections

Year	Estimated Market Potential	Assumed Market Penetration	Projected Revenue (USD billions)	Notes
2024	$4.4 billion (market size)	2%	$88 million	Initial commercial launch (if approved)
2025	Market growth continues	5%	$220 million	Expanding adoption
2026	Broader awareness, early adoption	10%	$440 million
2027	Increased uptake	15%	$660 million
2028	Market saturation continues	20%	$880 million	Approaching peak penetration

Note: These estimates rely on successful FDA approval, market acceptance, and payer reimbursement policies.

Development and Commercialization Costs

• Estimated R&D expenses for Phase III trials: $200-300 million
• Potential milestone payments to partners: $50-100 million
• Commercial launch expenses: $50-100 million

Licensing and Partnerships

Partnership agreements for distribution and commercialization could influence revenue streams. Prior collaborations or licensing deals could range from upfront payments of $50-150 million to revenue-sharing models.

What are the key risks impacting Resmetirom's financial outlook?

• Regulatory risk: Additional data requests or setbacks could delay approval.
• Market risk: Physician acceptance, payer reimbursement policies, and competition can limit market share.
• Clinical risk: Unforeseen safety or efficacy issues from Phase III data could hinder approval.
• Intellectual property: Patent protections lasting into the late 2030s are critical for maximizing revenue.

What is the timeline for commercialization and revenue realization?

• Anticipated FDA submission: 2024
• Potential approval: 2025 (assuming no delays)
• First commercial sales: mid to late 2025
• Revenue ramp-up: over 2-5 years post-approval, depending on market uptake

Comparative Analysis: Resmetirom versus Competitors

Drug	Status	Market Focus	Estimated Market Size (2022)	Key Differentiator
Resmetirom	Phase III pending approval	NASH	$4.4 billion	Liver-selective, oral, anti-fibrotic
Obeticholic acid (Ocaliva)	Approved (for another indication)	NASH, Fibrosis	N/A (marketed but off-label for NASH)	First-in-class FXR agonist
Aramchol	Phase III ongoing	NASH	Estimated, <$1 billion	Bile acid derivative, safety profile

Key Takeaways

• Resmetirom is nearing regulatory approval, with a targeted launch expected around 2025.
• The total market potential exceeds $4 billion, with upside driven by population growth and unmet needs.
• Financial revenue depends on successful trial outcomes, approval, payer coverage, and competitive positioning.
• Risks remain operational, clinical, and regulatory, requiring diligent risk management.

FAQs

Q1: When is Resmetirom expected to gain FDA approval?
A: The company anticipates submitting a BLA in 2024, with approval projected in 2025 assuming positive trial data.

Q2: How does Resmetirom compare to existing NASH therapies?
A: It offers a liver-specific, oral alternative with potential anti-fibrotic benefits, differentiating it from less targeted options.

Q3: What are the main hurdles for Resmetirom’s commercial success?
A: Securing regulatory approval, achieving physician adoption, securing reimbursement, and competing against pipeline candidates.

Q4: How significant is the NASH market financially?
A: It is projected to reach $10 billion globally by 2030, driven by rising prevalence and no approved therapies for all disease stages.

Q5: What strategies could boost Resmetirom’s market penetration?
A: Demonstrating long-term safety and efficacy, engaging payers early, and establishing strategic licensing agreements.

---

References

[1] FMI. (2022). Non-alcoholic Steatohepatitis (NASH) Market. Future Market Insights.
[2] Bloomberg Intelligence. (2023). Pharmaceutical Pipeline Analysis.
[3] U.S. Food and Drug Administration. (2023). Fast Track and Breakthrough Therapy Program Details.